The recent release of 13F reports from institutional investors has shed light on the shifting sands of Wall Street's investment landscape. These mandatory filings, required by the U.S. Securities and Exchange Commission (SEC) for institutions managing over $100 million in equity assets, provide a window into the portfolio adjustments of the financial world's heavyweights, including the likes of Berkshire Hathaway, Baillie G...
bowzerWoo_
OP
123456FEDCBA
:
yes I bought 4 at 28$ I sold on that last big drop to under 15$....lameeee . no growth just drop drop drop. all it's been doing the last year is steadily dropping. no recovery!!! sell!!
ForeverBean
OP
123456FEDCBA
:
A friend of mine knows members of the management team and speaks highly of their capabilities--that's all. I personally value the quality of management a lot when investing. So the cheaper it gets, the more I'm willing to buy.
$10x Genomics (TXG.US)$Not everthing is positive with this stock. I can see more pain and it will test to $10 by the end of Q3. Management is try, hope they will fix it. For long term I am positive and invest if it will show sign of reversal. Fundamental is nutral, but trend and sentiment both are negative for Q3.
10x Genomics Stock Forum
No comment yet